抗血管生成疗法及其与其他药物联合治疗晚期肝细胞癌的研究进展。
Study progression of anti-angiogenetic therapy and its combination with other agents for the treatment of advanced hepatocellular carcinoma.
作者信息
Gong Xinlei, Qin Shukui
机构信息
Department of Medical Oncology, PLA Cancer Center of Bayi Hospital Affiliated to Nanjing University of Chinese Medicine, Nanjing 210002, China.
出版信息
Hepatobiliary Surg Nutr. 2018 Dec;7(6):466-474. doi: 10.21037/hbsn.2018.11.04.
Abstract
Hepatocellular carcinoma (HCC) is a common malignancy worldwide and is especially prevalent in the Chinese population. Treatment of advanced HCC has posed a considerable challenge to clinicians and highly effective therapies remain elusive. Angiogenesis contributes greatly to the pathogenesis, invasion and metastasis of HCC. Therefore, anti-angiogenesis therapy could be instrumental to the treatment of HCC. In recent years, several anti-angiogenesis drugs have generated significant outcomes in a few key clinical studies, and in this light, anti-angiogenesis therapy has become a critical aspect of comprehensive treatment of HCC. In this article, to provide a reference for clinicians, we review these advances and discuss the future direction of development.
摘要
肝细胞癌（HCC）是全球常见的恶性肿瘤，在中国人群中尤为普遍。晚期HCC的治疗给临床医生带来了巨大挑战，高效的治疗方法仍然难以捉摸。血管生成在HCC的发病机制、侵袭和转移中起很大作用。因此，抗血管生成治疗可能有助于HCC的治疗。近年来，几种抗血管生成药物在一些关键临床研究中取得了显著成果，鉴于此，抗血管生成治疗已成为HCC综合治疗的关键方面。在本文中，为临床医生提供参考，我们回顾这些进展并讨论未来的发展方向。
相似文献
1
Study progression of anti-angiogenetic therapy and its combination with other agents for the treatment of advanced hepatocellular carcinoma.抗血管生成疗法及其与其他药物联合治疗晚期肝细胞癌的研究进展。
Hepatobiliary Surg Nutr. 2018 Dec;7(6):466-474. doi: 10.21037/hbsn.2018.11.04.
2
Role of anti-angiogenesis therapy in the management of hepatocellular carcinoma: The jury is still out.抗血管生成疗法在肝细胞癌治疗中的作用：尚无定论。
World J Hepatol. 2014 Dec 27;6(12):830-5. doi: 10.4254/wjh.v6.i12.830.
3
Angiogenesis in hepatocellular carcinoma: mechanisms and anti-angiogenic therapies.肝细胞癌中的血管生成：机制与抗血管生成治疗。
Cancer Biol Med. 2023 Jan 12;20(1):25-43. doi: 10.20892/j.issn.2095-3941.2022.0449.
4
Recent update on comprehensive therapy for advanced hepatocellular carcinoma.晚期肝细胞癌综合治疗的最新进展
World J Gastrointest Oncol. 2021 Aug 15;13(8):845-855. doi: 10.4251/wjgo.v13.i8.845.
5
Advances of Targeted Therapy for Hepatocellular Carcinoma.肝细胞癌靶向治疗的进展
Front Oncol. 2021 Jul 26;11:719896. doi: 10.3389/fonc.2021.719896. eCollection 2021.
6
Research Progresses of Targeted Therapy and Immunotherapy for Hepatocellular Carcinoma.肝癌的靶向治疗和免疫治疗的研究进展。
Curr Med Chem. 2021;28(16):3107-3146. doi: 10.2174/0929867327666201013162144.
7
Endothelial DGKG promotes tumor angiogenesis and immune evasion in hepatocellular carcinoma.内皮细胞二氢黄酮醇 4-还原酶促进肝细胞癌的肿瘤血管生成和免疫逃逸。
J Hepatol. 2024 Jan;80(1):82-98. doi: 10.1016/j.jhep.2023.10.006. Epub 2023 Oct 12.
8
Angiogenesis in Hepatocellular Carcinoma; Pathophysiology, Targeted Therapy, and Role of Imaging.肝细胞癌中的血管生成；病理生理学、靶向治疗及影像学的作用
J Hepatocell Carcinoma. 2020 Apr 23;7:77-89. doi: 10.2147/JHC.S224471. eCollection 2020.
9
Progress in systemic therapy of advanced hepatocellular carcinoma.晚期肝细胞癌全身治疗的进展
World J Gastroenterol. 2016 Aug 7;22(29):6582-94. doi: 10.3748/wjg.v22.i29.6582.
10
Glucometabolic Reprogramming in the Hepatocellular Carcinoma Microenvironment: Cause and Effect.肝细胞癌微环境中的糖代谢重编程：因果关系
Cancer Manag Res. 2020 Jul 17;12:5957-5974. doi: 10.2147/CMAR.S258196. eCollection 2020.
引用本文的文献
1
Unraveling the mechanism of core prescription in primary liver cancer: integrative analysis through data mining, network pharmacology, and molecular simulation.揭示原发性肝癌核心处方的作用机制：通过数据挖掘、网络药理学和分子模拟进行综合分析
In Silico Pharmacol. 2025 Apr 16;13(2):63. doi: 10.1007/s40203-025-00352-2. eCollection 2025.
2
Microwave ablation combined with apatinib and camrelizumab in patients with advanced hepatocellular carcinoma: A single-arm, preliminary study.微波消融联合阿帕替尼和卡瑞利珠单抗治疗晚期肝细胞癌的单臂初步研究。
Front Immunol. 2022 Oct 26;13:1023983. doi: 10.3389/fimmu.2022.1023983. eCollection 2022.
3
Hepatoprotective role of peroxisome proliferator-activated receptor-α in non-cancerous hepatic tissues following transcatheter arterial embolization.经导管动脉栓塞术后过氧化物酶体增殖物激活受体-α在非癌性肝组织中的肝保护作用
Open Life Sci. 2022 Aug 11;17(1):827-838. doi: 10.1515/biol-2022-0068. eCollection 2022.
4
Dicer Enhances Bevacizumab-Related Inhibition of Hepatocellular Carcinoma via Blocking the Vascular Endothelial Growth Factor Pathway.Dicer通过阻断血管内皮生长因子途径增强贝伐单抗对肝细胞癌的抑制作用。
J Hepatocell Carcinoma. 2021 Dec 29;8:1643-1653. doi: 10.2147/JHC.S327258. eCollection 2021.
5
Gene Expression Characteristics of Liver Tissue Reveal the Underlying Pathogenesis of Hepatocellular Carcinoma.肝组织基因表达特征揭示肝癌的潜在发病机制。
Biomed Res Int. 2021 Oct 4;2021:9458328. doi: 10.1155/2021/9458328. eCollection 2021.
6
Camrelizumab in combination with apatinib in second-line or above therapy for advanced primary liver cancer: cohort A report in a multicenter phase Ib/II trial.卡瑞利珠单抗联合阿帕替尼二线及以上治疗晚期原发性肝癌：一项多中心Ib/II 期试验的队列 A 报告。
J Immunother Cancer. 2021 Mar;9(3). doi: 10.1136/jitc-2020-002191.
7
Identification of bioactive anti-angiogenic components targeting tumor endothelial cells in Shenmai injection using multidimensional pharmacokinetics.运用多维药代动力学鉴定参麦注射液中靶向肿瘤内皮细胞的生物活性抗血管生成成分。
Acta Pharm Sin B. 2020 Sep;10(9):1694-1708. doi: 10.1016/j.apsb.2019.12.011. Epub 2019 Dec 18.
8
Programmed cell death protein 1/programmed death ligand-1 checkpoint blockade meets patient-derived organoids.程序性细胞死亡蛋白1/程序性死亡配体1检查点阻断与患者来源的类器官相结合。
Ann Transl Med. 2019 Dec;7(Suppl 8):S287. doi: 10.21037/atm.2019.11.76.
9
m6A demethylase FTO promotes hepatocellular carcinoma tumorigenesis via mediating PKM2 demethylation.m6A去甲基化酶FTO通过介导丙酮酸激酶M2（PKM2）去甲基化促进肝细胞癌的肿瘤发生。
Am J Transl Res. 2019 Sep 15;11(9):6084-6092. eCollection 2019.
本文引用的文献
1
Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma.仑伐替尼联合帕博利珠单抗治疗不可切除肝细胞癌的 Ib 期研究。
J Clin Oncol. 2020 Sep 10;38(26):2960-2970. doi: 10.1200/JCO.20.00808. Epub 2020 Jul 27.
2
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.全球癌症统计数据 2018：GLOBOCAN 对全球 185 个国家/地区 36 种癌症的发病率和死亡率的估计。
CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
3
Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial.序贯索拉非尼后regorafenib 治疗 HCC 的结果：来自 III 期 RESORCE 试验的附加分析。
J Hepatol. 2018 Aug;69(2):353-358. doi: 10.1016/j.jhep.2018.04.010. Epub 2018 Apr 26.
4
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.乐伐替尼与索拉非尼用于不可切除肝细胞癌患者一线治疗的比较：一项随机、III 期非劣效性试验。
Lancet. 2018 Mar 24;391(10126):1163-1173. doi: 10.1016/S0140-6736(18)30207-1.
5
[Report of Cancer Incidence and Mortality in China, 2014].《2014年中国癌症发病与死亡报告》
Zhonghua Zhong Liu Za Zhi. 2018 Jan 23;40(1):5-13. doi: 10.3760/cma.j.issn.0253-3766.2018.01.002.
6
The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From the Global Burden of Disease Study 2015.2015 年全球疾病负担研究：1990 年至 2015 年全球、区域和国家一级原发性肝癌及相关病因负担。
JAMA Oncol. 2017 Dec 1;3(12):1683-1691. doi: 10.1001/jamaoncol.2017.3055.
7
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.纳武利尤单抗治疗晚期肝细胞癌患者（CheckMate 040）：一项开放标签、非对照、1/2 期剂量递增和扩展试验。
Lancet. 2017 Jun 24;389(10088):2492-2502. doi: 10.1016/S0140-6736(17)31046-2. Epub 2017 Apr 20.
8
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.regorafenib 用于索拉非尼治疗后进展的肝细胞癌患者（RESORCE）：一项随机、双盲、安慰剂对照、3 期试验。
Lancet. 2017 Jan 7;389(10064):56-66. doi: 10.1016/S0140-6736(16)32453-9. Epub 2016 Dec 6.
9
Ramucirumab as Second-Line Treatment in Patients With Advanced Hepatocellular Carcinoma: Analysis of REACH Trial Results by Child-Pugh Score.雷莫西尤单抗作为晚期肝细胞癌患者的二线治疗：按Child-Pugh评分对REACH试验结果的分析
JAMA Oncol. 2017 Feb 1;3(2):235-243. doi: 10.1001/jamaoncol.2016.4115.
10
Safety and Pharmacokinetics of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma.乐伐替尼在晚期肝细胞癌患者中的安全性和药代动力学
Clin Cancer Res. 2016 Mar 15;22(6):1385-94. doi: 10.1158/1078-0432.CCR-15-1354. Epub 2015 Oct 23.
Zotero 插件